Table 2.

MRs estimates of log (acute infarct volumes) values by linear regression

Characteristic	MR		Adjusted MR
	95% CI	P	95% CI	P
Entire cohort
Any migraine vs. no migraine	1.74 (1.30–2.35)	2.7×10-4	1.80 (1.33–2.45)*	≤0.001
Migraine without aura vs. no migraine	1.28 (0.90–1.82)	0.162	1.29 (0.91–1.82)*	0.157
Migraine with aura vs. no migraine	3.04 (1.94–4.76)	1.7×10-6	3.62 (2.28–5.74)*	7.3×10-8
Male
Any migraine vs. no migraine	1.77 (1.16–2.72)	0.009	1.95 (1.24–3.06)*	0.003
Migraine without aura vs. no migraine	1.41 (0.84–2.35)	0.193	1.40 (0.83–2.35)*	0.205
Migraine with aura vs. no migraine	2.66 (1.38–5.14)	0.003	3.76 (1.89–7.49)*	≤0.001
Female
Any migraine vs. no migraine	1.59 (1.04–2.42)	0.033	1.64 (1.07–2.52)†	0.024
Migraine without aura vs. no migraine	1.10 (0.68–1.79)	0.696	1.14 (0.70–1.84)†	0.598
Migraine with aura vs. no migraine	3.11 (1.67–5.78)	4.2×10-4	3.52 (1.87–6.62)†	≤0.001

MR, median ratio; CI, confidence interval.

^*Adjusted by age, alcohol consumption, time from stroke onset to magnetic resonance imaging, presumed etiology of brain ischemia (categorized according to the Trial of Org 10172 in Acute Stroke Treatment [TOAST] criteria), patent foramen ovale, large vessel occlusion (occlusion vs. non-occlusion), acute reperfusion therapy (intravenous tissue plasminogen activator and/or mechanical thrombectomy vs. no reperfusion therapy), and arterial recanalization (complete recanalization [Thrombolysis in Cerebral Infarction score of IIb or higher at the end of the endovascular procedure [18]] vs. other);

^†Adjusted as in males (*) and oral contraceptive use.